Really excited to be co-hosting the 2025 World Laughing Championship with 2023 World Laughing Champion Carla H Brown!

#Worldlaughingchampionship

Tickets available now!

(simpli.events/e/WorldLaugh...

#Wlc25 #Worldlaughingchampionship

Truly wonderful and inspirational day representing #AFBI at the Women’s Leadership Conference #WLC25 @AFBI_NI @IoDNI

Targeted Therapies for NSCLC With Nonclassical EGFR Mutations Grow Increasingly Personalized The variety of nonclassical EGFR mutations in NSCLC necessitates the development of unique treatment strategies based on individual mutational profiles.

Targeted Therapies for NSCLC With Nonclassical EGFR Mutations Grow Increasingly Personalized
#gotoPER #WLC25 #LCSM
www.onclive.com/view/targete...

Next-Generation Sequencing Data Inform IO Treatment Sequencing in NSCLC KEAP1 and STK11 have emerged as potential biomarkers of response to immuno-oncology combinations in frontline NSCLC.

Next-Generation Sequencing Data Inform IO Treatment Sequencing in NSCLC #WLC25 #gotoPER #lcsm www.onclive.com/view/next-ge...

Dr Mekhail on a Case Study of Early-Stage, Nonmetastatic Lung Cancer Tarek Mekhail, MD, MSc, FRCSI, FRCSEd, discusses a case study of a patient with early-stage, nonmetastatic lung adenocarcinoma.

Tarek Mekhail, MD, MSc, FRCSI, FRCSEd, discusses a case study of a patient with early-stage, nonmetastatic lung adenocarcinoma. #gotoPER #WLC25 #lcsm
www.onclive.com/view/dr-mekh...

Dr Levy on the Development and Clinical Use of ADCs in NSCLC Benjamin P. Levy, MD, discusses the current clinical and developmental statuses of several ADCs for patients with non–small cell lung cancer.

Benjamin P. Levy, MD, discusses the current clinical and developmental statuses of several ADCs for patients with non–small cell lung cancer. @benlevylungdoc.bsky.social @hopkinsmedicine.bsky.social #gotoPER #WLC25 #lcsm
www.onclive.com/view/dr-levy...

Thanks to Balazs Halmos, MD, and Susan Scott, MD, for interviewing with us about their #WLC25 Medical Crossfire debate on treatment selection in EGFR-mutant NSCLC! Check back on our site for their insights! @hopkinsmedicine.bsky.social #gotoPER #lcsm
www.onclive.com/conference/w...

Thank you to Dr Tarek Mekhail for speaking with us during #WLC25 about lung cancer case studies! Check out our site for more from the meeting! #gotoPER #lcsm
www.onclive.com/conference/w...

A huge thanks to @benlevylungdoc.bsky.social, of @hopkinsmedicine.bsky.social, for stopping by during #WLC25 to talk all things ADCs in lung cancer! See our site for ADC insights and more! #gotoPER #lcsm
www.onclive.com/conference/w...

Thank you to Julie Brahmer, MD, one of the #WLC25 meeting chairs, for joining us for an interview about highlights from the meeting and future advances in lung oncology! See our site for more conference insights! @hopkinsmedicine.bsky.social #gotoPER #lcsm
www.onclive.com/conference/w...

The third and final day of #WLC25 is here! Stay tuned to see how the meeting wraps up, and follow along on our site as we share more KOL #lcsm insights from the meeting over the next few days! #gotoPER
www.onclive.com/conference/w...

Shields Spotlights Lessons Learned in Limited-Stage SCLC and Areas Ripe for Further Research Misty Shields, MD, PhD, provides a comprehensive overview of key updates in. the management of limited-stage small cell lung cancer.

Shields Spotlights Lessons Learned in Limited-Stage SCLC and Areas Ripe for Further Research #WLC25 #gotoPER #lcsm www.onclive.com/view/shields...

Russell Hales, MD, discusses clinical data that challenge the use of post-operative radiotherapy in patients with non–small cell lung cancer. #gotoPER #WLC25 #lcsm
www.onclive.com/view/dr-hale...

Dr Rodriguez on a Case Study of EGFR-Mutated NSCLC Estelamari Rodriguez, MD, MPH, discusses a case study of a patient with non–small cell lung cancer harboring an EGFR L858R mutation and a TP53 mutation.

Estelamari Rodriguez, MD, MPH, discusses a case study of a patient with non–small cell lung cancer harboring an EGFR L858R mutation and a TP53 mutation. @latinamd.bsky.social #gotoPER #WLC25 #lcsm
www.onclive.com/view/dr-rodr...

Expanded Targets, Synergistic Regimens Are Needed to Propel NSCLC Beyond Anti–PD-1 Therapy Melissa L. Johnson, MD, discusses the evolution of immunotherapy approaches beyond PD-1 inhibition in lung cancer.

Expanded Targets, Synergistic Regimens Are Needed to Propel NSCLC Beyond Anti–PD-1 Therapy #gotoPER #WLC25 #lcsm www.onclive.com/view/expande...

Data Help Refine Optimal Radiotherapy Approaches in Small Cell Lung Cancer Walter J. Curran, MD, discusses the evolving use of radiotherapy in small cell cancer and data supporting its optimal use.

Data Help Refine Optimal Radiotherapy Approaches in Small Cell Lung Cancer #WLC25 #lcsm #oncology www.onclive.com/view/data-he...

We've seen lots of fascinating talks at #WLC25! Speakers have brought attention to lung cancer rates in women & nonsmokers, & multidisciplinary considerations are at the core of many conversations. Head to our site to see some of these insights! #gotoPER #lcsm
www.onclive.com/conference/w...

Thanks to Russell Hales, MD, of @HopkinsMedicine for stopping by to discuss thought-provoking questions about the use of post-operative radiation therapy in lung cancer! See our site for more from the meeting! #gotoPER #WLC25 #lcsm
www.onclive.com/conference/w...

Thank you to @latinamd.bsky.social, of Sylvester Comprehensive Cancer Center, for stopping by during #WLC25 to talk case-based discussions and the importance of ADCs and biomarkers in lung cancer! Check out our site for more from the meeting! #gotoPER #lcsm
www.onclive.com/conference/w...

Day 2 of the 22nd Annual Winter Lung Cancer Conference is here! With a view like this, who wouldn't want to soak up the latest lung cancer insights? Check out our site throughout the day for exclusive meeting updates! #gotoPER #WLC25 #lcsm
www.onclive.com/conference/w...

Dr Shields on Key ADRIATIC Trial Data With Adjuvant Durvalumab in LS-SCLC Misty D. Shields, MD, PhD, discusses the implications of the ADRIATIC trial of adjuvant therapy with durvalumab vs placebo in patients with LS-SCLC.

WATCH: Misty Shields, MD, PhD, discusses the implications of the ADRIATIC trial of adjuvant therapy with durvalumab vs placebo in patients with LS-SCLC. #gotoPER #WLC25 #lcsm
www.onclive.com/view/dr-shie...

Dr Langer on the Evolution of Adjuvant Immunotherapy in NSCLC Corey J. Langer, MD, discusses how the use of adjuvant immunotherapy has affected the resectable NSCLC treatment paradigm.

Corey Langer, MD discusses how the use of adjuvant immunotherapy has affected the resectable NSCLC treatment paradigm. @pennmedicine.bsky.social #gotoPER #WLC25 #lcsm
www.onclive.com/view/dr-lang...

Thank you to @coreylanger.bsky.social, of @pennmedicine.bsky.social, for speaking with us at #WLC25 about adjuvant NSCLC treatment! See our site for more #lcsm insights. #gotoPER
www.onclive.com/conference/w...

A huge thanks to Misty Shields, MD, PhD, of Indiana University, for stopping by during #WLC25 to chat about advances in SCLC management! Check out our site for more from the meeting! #lcsm #gotoPER
www.onclive.com/conference/w...

The first sessions of #WLC25 have begun! Follow along to see our coverage of expert #lcsm insights from the meeting! #gotoPER
www.onclive.com/conference/w...

We have landed in sunny Hollywood, Florida for the 22nd Annual Winter Lung Cancer Conference! Follow along on our site for exclusive #lcsm insights all weekend! #gotoPER #WLC25
www.onclive.com/conference/w...

PER’s Winter Lung meeting is coming up at the end of the month, in Hollywood, Florida. Lots of great speakers. Register today for FREE using RIELY as a discount code! bit.ly/3CS06Gf #gotoPER #WLC25 #lungcancer #winterlung